TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01784562
Drug: Adempas (Riociguat, BAY63-2521)
Normalized name: Adempas
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
Study: NCT05694364
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is an antimetabolite given prior to lymphodepletion.
Study: NCT04795245
Drug: afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: afatinib
Study: NCT05755113
Drug: Tigilanol Tiglate
Normalized name: Tigilanol Tiglate
DrugBank: Tigilanol tiglate (DB18800)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
Study: NCT06139380
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is medication which is commonly used for sedation in the emergency department. At the analgesic dose, this medication can be used to reduce the pain via other routes such as intranasal.
Study: NCT06139380
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sterile water was administered via syringe.
Study: NCT05090410
Drug: filgotinib 200mg/day
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
Study: NCT05090410
Drug: subcutaneous tocilizumab 162mg/biweekly
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
Study: NCT00000637
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000637
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05725798
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.
Study: NCT04993027
Drug: Vancomycin Powder
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.
Study: NCT05022004
Drug: Brinzolamide ophthalmic suspension
Normalized name: Brinzolamide Ophthalmic Suspension
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
Study: NCT04631471
Drug: Ibudilast
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
Study: NCT04728971
Drug: Micafungin Sodium 50 MG Injection
Normalized name: micafungin sodium 50 MG Injection
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Give Micafungin 150 mg/d within 24 hours after liver transplantation.
Study: NCT04728971
Drug: Caspofungin Acetate
Normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Give Caspofungin 35 mg/d lasts 1 week after liver transplantation.
Study: NCT04346394
Drug: Yohimbine HCl
Normalized name: yohimbine HCl
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning
Study: NCT06671990
Drug: Vericiguat
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
Study: NCT05238896
Drug: Baricitinib Oral Tablet [Olumiant]
Normalized name: baricitinib Oral Tablet [Olumiant]
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib 4 mg/d oral route for 42 days
Study: NCT05732155
Drug: methylenedioxymethamphetamine
Normalized name: Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of MDMA HCl, in participants with PTSD and moral injury, in individual and group treatment settings
Study: NCT04656964
Drug: remimazolam tosilate group
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).
Study: NCT04656964
Drug: Midazolam group
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
Study: NCT04628793
Drug: PF-07258669
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
Study: NCT06186414
Drug: SIM0237 and BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
Study: NCT06186414
Drug: SIM0237 and BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
Study: NCT04518293
Drug: Telmisartan 20 mg/amlodipine 2.5 mg .
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04518293
Drug: telmisartan 40 mg/amlodipine 5 mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT05276219
Drug: Furosemide Injection
Normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A diuretic (iv furosemide) strategy for decongestion in acute heart failure
Study: NCT05276219
Drug: Isosorbide Dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
Study: NCT05276219
Drug: Furosemide and isosorbide dinitrate
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
Study: NCT04897412
Drug: CBL-514 Injection
Normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
Study: NCT06472895
Drug: AK112 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A novel PD-1/VEGF bispecific antibody; RP2D intravenously (IV)，Q3W
Study: NCT04760314
Drug: Lebrikizumab
Normalized name: Lebrikizumab
DrugBank: Lebrikizumab (DB11914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05673603
Drug: Brensocatib
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05778305
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a central sympatholytic drug
Study: NCT04934670
Drug: T-Guard
Normalized name: T-Guard
DrugBank: T-Guard (DB18357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
Study: NCT04934670
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
Study: NCT06627751
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06627751
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06627270
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive metronidazole (500 mg t.i.d. x 10 days)
Study: NCT06627647
Drug: Rilvegostomig
Normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT06627647
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT06627647
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study: NCT06627647
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study: NCT06627647
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT05766631
Drug: Methadone Treatment-As-Usual
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
Study: NCT05680129
Drug: Ecnoglutide high dosage
Normalized name: high-density polyethylene
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT05680129
Drug: Ecnoglutide low dosage
Normalized name: low-density polyethylene
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT05680129
Drug: Dulaglutide
Normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered subcutaneously
Study: NCT05680129
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT06573151
Drug: Selinexor, anti-PD-1 antibody and P-GemOx
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);
Study: NCT05942508
Drug: TQB2450 Injection + Anlotinib Hydrochloride Capsules
Normalized name: terbinafine
DrugBank: Anlotinib (DB11885)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody
Study: NCT04720417
Drug: Defactinib Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Defactinib (DB12282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06148935
Drug: Vericiguat (Verquvo, BAY1021189)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol
Study: NCT04951856
Drug: Evolocumab 140 MG/ML
Normalized name: evolocumab 140 MG/ML
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
Study: NCT06622941
Drug: ONO-4538
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 2 weeks
Study: NCT06691035
Drug: Elacestrant
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 345 mg (or 86 mg tablets) orally daily during vaccination and continued after until progression.~Cycle Length 28 days (4 weeks)
Study: NCT06692738
Drug: Rilvegostomig
Normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT06692738
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT06692738
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study: NCT06692738
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study: NCT06692738
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
Study: NCT06692348
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06692426
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus host disease (GVHD) as well as allograft rejection in the setting of allogeneic hematopoietic stem cell transplantation.
Study: NCT04528082
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive apremilast orally.
Study: NCT06532383
Drug: PF-07940369
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk powder for extemporaneous preparation for oral solutions.
Study: NCT05240950
Drug: Anti-CEA CAR-T Cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10\^6/kg, 3×10\^6/kg, and 6×10\^6/kg using a standard 3+3 design and preliminarily observe the efficacy.
Study: NCT05019703
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06692361
Drug: Escitalopram (Lexapro)
Normalized name: escitalopram Oral Tablet [Lexapro]
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both the experimental group and the placebo group were treated with the maximum tolerated dose of escitalopram.
Study: NCT04881110
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one.
Study: NCT06246344
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (825 mg/m2, po, twice daily)
Study: NCT06502977
Drug: Tarlatamab
Normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05897138
Drug: Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
Normalized name: furosemide
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle
Study: NCT05645484
Drug: 18F-PFPN
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-PFPN (dose: 3.0-5.4 MBq/kg) will be injected intravenously prior to imaging.
Study: NCT05645484
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18F-FDG (dose: 3.7-5.4 MBq/kg) will be injected intravenously prior to imaging.
Study: NCT00000711
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000711
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06164795
Drug: Zoledronate
Normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion
Study: NCT06164795
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injection
Study: NCT06164795
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous injection
Study: NCT06164795
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous injection
Study: NCT05346952
Drug: TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
Study: NCT05868993
Drug: Dose of 0.5% Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose varied by 5mL of 0.5% Ropivacaine
Study: NCT05654662
Drug: Corsodyl Original Dentifrice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million \[ppm\] Fluoride ion \[F\])
Study: NCT05654662
Drug: Colgate Cavity Protection Dentifrice
Normalized name: sodium fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
Study: NCT05890963
Drug: ART
Normalized name: MART1
DrugBank: Melanoma antigen recognized by T-cells 1 (DB15081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART is a combination of three or more drugs from different classes of antiretroviral medication.
Study: NCT06326463
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/m2, Day -4, -3 and -2
Study: NCT06326463
Drug: CD70-CAR T cell infusion (Autologous)
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0 or +1
Study: NCT06326463
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide
Study: NCT06695507
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive ruxolitinib for 6 months.
Study: NCT06630221
Drug: Eltrombopag (EPAG)
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg, 28-day cycles, 3+ cycles
Study: NCT06694675
Drug: Sevoflurane (Volatile Anesthetic)
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane 1%\~3.5%
Study: NCT06694675
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 9\~15mg/kg/h
Study: NCT06630260
Drug: Avutometinib
Normalized name: Avutometinib
DrugBank: Avutometinib (DB15254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as 0.8mg capsules.
Study: NCT06630260
Drug: Defactinib
Normalized name: Defactinib
DrugBank: Defactinib (DB12282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as 200mg tablets.